Nature Communications (Jul 2024)
A multi-classifier system integrated by clinico-histology-genomic analysis for predicting recurrence of papillary renal cell carcinoma
- Kang-Bo Huang,
- Cheng-Peng Gui,
- Yun-Ze Xu,
- Xue-Song Li,
- Hong-Wei Zhao,
- Jia-Zheng Cao,
- Yu-Hang Chen,
- Yi-Hui Pan,
- Bing Liao,
- Yun Cao,
- Xin-Ke Zhang,
- Hui Han,
- Fang-Jian Zhou,
- Ran-Yi Liu,
- Wen-Fang Chen,
- Ze-Ying Jiang,
- Zi-Hao Feng,
- Fu-Neng Jiang,
- Yan-Fei Yu,
- Sheng-Wei Xiong,
- Guan-Peng Han,
- Qi Tang,
- Kui Ouyang,
- Gui-Mei Qu,
- Ji-Tao Wu,
- Ming Cao,
- Bai-Jun Dong,
- Yi-Ran Huang,
- Jin Zhang,
- Cai-Xia Li,
- Pei-Xing Li,
- Wei Chen,
- Wei-De Zhong,
- Jian-Ping Guo,
- Zhi-Ping Liu,
- Jer-Tsong Hsieh,
- Dan Xie,
- Mu-Yan Cai,
- Wei Xue,
- Jin-Huan Wei,
- Jun-Hang Luo
Affiliations
- Kang-Bo Huang
- Department of Urology, First Affiliated Hospital, Sun Yat-sen University
- Cheng-Peng Gui
- Department of Urology, First Affiliated Hospital, Sun Yat-sen University
- Yun-Ze Xu
- Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University
- Xue-Song Li
- Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center
- Hong-Wei Zhao
- Department of Urology, Affiliated Yantai Yuhuangding Hospital, Qingdao University
- Jia-Zheng Cao
- Department of Urology, Jiangmen Hospital, Sun Yat-sen University
- Yu-Hang Chen
- Department of Urology, First Affiliated Hospital, Sun Yat-sen University
- Yi-Hui Pan
- Department of Urology, The Third Affiliated Hospital of Soochow University
- Bing Liao
- Department of Pathology, First Affiliated Hospital, Sun Yat-sen University
- Yun Cao
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer center
- Xin-Ke Zhang
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer center
- Hui Han
- Department of Urology, Sun Yat-sen University Cancer center
- Fang-Jian Zhou
- Department of Urology, Sun Yat-sen University Cancer center
- Ran-Yi Liu
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer center
- Wen-Fang Chen
- Department of Pathology, First Affiliated Hospital, Sun Yat-sen University
- Ze-Ying Jiang
- Department of Pathology, First Affiliated Hospital, Sun Yat-sen University
- Zi-Hao Feng
- Department of Urology, First Affiliated Hospital, Sun Yat-sen University
- Fu-Neng Jiang
- Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People’s Hospital, School of Medicine, South China University of Technology
- Yan-Fei Yu
- Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center
- Sheng-Wei Xiong
- Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center
- Guan-Peng Han
- Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center
- Qi Tang
- Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center
- Kui Ouyang
- Department of Urology, Affiliated Yantai Yuhuangding Hospital, Qingdao University
- Gui-Mei Qu
- Department of Pathology, Affiliated Yantai Yuhuangding Hospital, Qingdao University
- Ji-Tao Wu
- Department of Urology, Affiliated Yantai Yuhuangding Hospital, Qingdao University
- Ming Cao
- Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University
- Bai-Jun Dong
- Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University
- Yi-Ran Huang
- Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University
- Jin Zhang
- Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University
- Cai-Xia Li
- School of Mathematics and Computational Science, Sun Yat-sen University
- Pei-Xing Li
- School of Mathematics and Computational Science, Sun Yat-sen University
- Wei Chen
- Department of Urology, First Affiliated Hospital, Sun Yat-sen University
- Wei-De Zhong
- Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People’s Hospital, School of Medicine, South China University of Technology
- Jian-Ping Guo
- Institute of Precision Medicine, First Affiliated Hospital, Sun Yat-sen University
- Zhi-Ping Liu
- Department of Internal Medicine and Department of Molecular Biology, University of Texas Southwestern Medical Center at Dallas
- Jer-Tsong Hsieh
- Department of Urology, University of Texas Southwestern Medical Center at Dallas
- Dan Xie
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer center
- Mu-Yan Cai
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer center
- Wei Xue
- Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University
- Jin-Huan Wei
- Department of Urology, First Affiliated Hospital, Sun Yat-sen University
- Jun-Hang Luo
- Department of Urology, First Affiliated Hospital, Sun Yat-sen University
- DOI
- https://doi.org/10.1038/s41467-024-50369-y
- Journal volume & issue
-
Vol. 15,
no. 1
pp. 1 – 12
Abstract
Abstract Integrating genomics and histology for cancer prognosis demonstrates promise. Here, we develop a multi-classifier system integrating a lncRNA-based classifier, a deep learning whole-slide-image-based classifier, and a clinicopathological classifier to accurately predict post-surgery localized (stage I–III) papillary renal cell carcinoma (pRCC) recurrence. The multi-classifier system demonstrates significantly higher predictive accuracy for recurrence-free survival (RFS) compared to the three single classifiers alone in the training set and in both validation sets (C-index 0.831-0.858 vs. 0.642-0.777, p < 0.05). The RFS in our multi-classifier-defined high-risk stage I/II and grade 1/2 groups is significantly worse than in the low-risk stage III and grade 3/4 groups (p < 0.05). Our multi-classifier system is a practical and reliable predictor for recurrence of localized pRCC after surgery that can be used with the current staging system to more accurately predict disease course and inform strategies for individualized adjuvant therapy.